SCHEMBL9747620

SCHEMBL9747620

COc1ccc2c(C(C)=O)cccc2c1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 5/20 0.55
MTNR1B P49286 3/20 0.55
ALDH1A1 P00352 3/20 0.53
CYP3A4 P08684 1/20 0.53
HPGD P15428 1/20 0.53
MAPK1 P28482 1/20 0.53
CDC25B P30305 1/20 0.52
KDR P35968 3/20 0.52
AURKA O14965 1/20 0.52
MET P08581 1/20 0.52
TEK Q02763 1/20 0.52
AURKB Q96GD4 1/20 0.52
CNR2 P34972 4/20 0.51
KDM4E B2RXH2 1/20 0.50
CYP1A2 P05177 1/20 0.48
CYP2A6 P11509 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10856546 0.87 MTNR1A (0.70) MTNR1AMTNR1BALDH1A1CYP3A4HPGD
SCHEMBL2510203 0.87 CDC25B (0.64) MTNR1AMTNR1BALDH1A1HPGDCDC25B
SCHEMBL31613816 0.87 CDC25B (0.64) MTNR1AMTNR1BALDH1A1HPGDCDC25B
SCHEMBL31392475 0.87 MTNR1A (0.70) MTNR1AMTNR1BALDH1A1CYP3A4HPGD
SCHEMBL31613069 0.85 KDR (0.67) MTNR1AMTNR1BALDH1A1CDC25BKDR
SCHEMBL2237855 0.85 MTNR1A (0.56) MTNR1AMTNR1BALDH1A1HPGDCDC25B
SCHEMBL2509951 0.85 MTNR1A (0.52) MTNR1AMTNR1BCDC25BKDRAURKA
SCHEMBL27792854 0.83 CYP1A2 (0.48) MTNR1AMTNR1BCDC25BKDRAURKA
SCHEMBL11739020 0.83 MTNR1A (0.51) MTNR1AMTNR1BCDC25BKDRAURKA
SCHEMBL11470996 0.83 CNR2 (0.54) MTNR1AMTNR1BCDC25BKDRAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017066103-A1 NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS AURIMMED PHARMA, INC. (US) 2017-04-20 WO disclosed
WO-2014083156-A2 HYDROCARBON MARKERS O'REILLY JOHN (IE) 2014-06-05 WO disclosed
WO-2014083156-A2 HYDROCARBON MARKERS O'REILLY JOHN (IE) 2014-06-05 WO disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed
WO-2010038465-A1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF 旭化成ファーマ株式会社 (JP) 2010-04-08 WO disclosed
EP-0511152-A2 Quinoxaline compounds, their preparation and use NOVO NORDISK A/S (DK) 1992-10-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof RELA, NFKBIA, NFKB2 MTNR1A 689/4885MTNR1B 811/4885ALDH1A1 1380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.